CITIC Securities recommends a strategic focus on Chinese innovative drug companies in the second half of 2026. Their analysis identifies three key categories of companies to prioritize: established leaders with increasing innovative drug revenue and strong commercialization capabilities, innovative platforms with globally competitive pipeline candidates in late-stage clinical trials, and growth-oriented biotechs with differentiated mechanisms and clear catalysts. The firm also notes a significant undervaluation in gold prices and gold stocks following the US-Iran conflict, projecting a price range of $4000-$4500 per ounce for Q3 2026, with potential upside to $4500-$5000 if interest rate expectations are fully revised. AI
RANK_REASON Analyst report providing investment recommendations and market outlook.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
